Catherine M. Vaczy Net Worth

The estimated Net Worth of Catherine M Vaczy is at least $773 Mille dollars as of 21 April 2023. Ms Vaczy owns over 20,000 units of Genprex Inc stock worth over $127,200 and over the last 4 years she sold GNPX stock worth over $0. In addition, she makes $646,021 as Exec. VP e Gen. Counsel & Chief Strategy Officer at Genprex Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Vaczy GNPX stock SEC Form 4 insiders trading

Ms has made over 1 trades of the Genprex Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 20,000 units of GNPX stock worth $21,400 on 21 April 2023.

The largest trade she's ever made was buying 20,000 units of Genprex Inc stock on 21 April 2023 worth over $21,400. On average, Ms trades about 5,000 units every 0 days since 2021. As of 21 April 2023 she still owns at least 265,000 units of Genprex Inc stock.

You can see the complete history of Ms Vaczy stock trades at the bottom of the page.

Ms. Catherine M. Vaczy biography

Catherine M. Vaczy is the Exec. VP, Gen. Counsel & Chief Strategy Officer at Genprex Inc.

What is the salary of Ms Vaczy?

As the Exec. VP e Gen. Counsel & Chief Strategy Officer of Genprex Inc, the total compensation of Ms Vaczy at Genprex Inc is $646,021. There are 3 executives at Genprex Inc getting paid more, with Ryan Confer having the highest compensation of $1,004,400.

How old is Ms Vaczy?

Ms Vaczy is 60, she's been the Exec. VP e Gen. Counsel & Chief Strategy Officer of Genprex Inc since . There are 6 older and 5 younger executives at Genprex Inc. The oldest executive at Genprex Inc is William Wilson, 70, who is the Independent Director.

What's Ms Vaczy's mailing address?

Catherine's mailing address filed with the SEC is 3300 BEE CAVE ROAD, #650-227, AUSTIN, TX, 78746.

Insiders trading at Genprex Inc

Over the last 7 years, insiders at Genprex Inc have traded over $0 worth of Genprex Inc stock and bought 156,300 units worth $607,092 . The most active insiders traders include Ryan M. Confer, Christy M. Nance e Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of $14,575. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth $20,140.

What does Genprex Inc do?

genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur

Complete history of Ms Vaczy stock trades at Genprex Inc

Genprex Inc executives and stock owners

Genprex Inc executives and other stock owners filed with the SEC include:

• Ryan Confer,
  Chief Financial Officer
• John Rodney Varner,
  Co, Founder, Pres, CEO, Sec. & Chairman
• J. Rodney Varner,
  Chairman of the Board, President, Chief Executive Officer, Secretary
• Catherine M. Vaczy,
  Exec. VP, Gen. Counsel & Chief Strategy Officer
• Catherine M. Vaczy Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer
• Ryan M. Confer M.S.,
  Chief Financial Officer
• William Wilson,
  Independent Director
• Jose Moreno Toscano,
  Independent Director
• Brent Longnecker,
  Independent Director
• Catherine Vaczy,
  Executive Vice President, Chief Strategy Officer
• Michael Redman,
  Chief Operating Officer, Executive Vice President
• David M. Schloss,
  Sr. VP of HR
• Greg Jancarik C.M.A., CPA, M.B.A.,
  Corp. Controller
• Dr. Mark S. Berger M.D.,
  Chief Medical Officer
• Dr. Hemant Kumar C.P.M., EMBA, Ph.D.,
  Chief Manufacturing & Technology Officer
• Dr. Jack A. Roth F.A.C.S., FACS, M.D.,
  Chairman of Scientific & Medical Advisory Board
• Dr. William E. Gannon Jr.,
  Member of Clinical Advisory Board & VP of Regulatory Affairs
• Thomas C. Gallagher Esq.,
  Sr. VP of Intellectual Property & Licensing
• Kalyn Dabbs,
  Sr. Mang. of Communications & Marketing
• Christy M. Nance,
  10% owner
• Jack A Roth,
  10% owner
• Viet An Hoan Ly,
  10% owner
• Inc. Genprex,,
  Chief Executive Officer
• Robert W. Pearson,
  Director
• David E. Friedman,
  Director
• Julien L Pham,
  President & COO
• Mark Stanley Berger,
  Chief Medical Officer
• Hermant Kumar,
  Chief Mfgr & Tech Officer